Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Beauvechain – page 60

1 944 clinical trials in Beauvechain, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Beauvechain at a glance
1 944
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 944 trials in Beauvechain

Open in trial search

Study on Imaging Non-Small Cell Lung Cancer Using 68GaNOTA-Anti-MMR VHH2 in Patients

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:68GaNOTA-anti-MMR-VHH2
  • Sponsor:UZ Brussel

Study on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Abatacept
  • Sponsor:IRCCS Istituto Giannina Gaslini

Study on the Effects of Filgotinib for Children and Teenagers with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Colitis ulcerative+1

Recruiting

Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged ≥12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Hypersomnia

Not yet recruiting

Phase 3 Randomized Double‑Blind Study of Pitolisant versus Placebo for Safety and Efficacy in Adults with Idiopathic Hypersomnia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pitolisant
  • Sponsor:Harmony Biosciences Management Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

A study to evaluate the effectiveness and safety of usnoflast in adults with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Usnoflast
  • Sponsor:Zydus Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Beauvechain

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management strategies in primary care settings. The studies examine optimal approaches for patients with functional dyspepsia and reflux conditions.

  • PPI De-prescribing Strategies
  • Gastrointestinal Health Management
  • Primary Care Interventions

Investigations compare different therapeutic approaches, including on-demand medication use and alternative treatments, to improve long-term patient outcomes in acid-related disorders.

02 Primary Care Medicine

Studies evaluating the effectiveness of various medication discontinuation protocols for patients with chronic heartburn and related conditions. Research aims to establish optimal treatment pathways.

  • Medication Management
  • Patient-Centered Care
  • Treatment Optimization

The research explores alternative therapeutic options and their impact on patient well-being and quality of life.

03 Digestive Health

Clinical investigations examining the management of acid reflux and related conditions through various therapeutic approaches, including traditional and alternative treatment methods.

  • Symptom Management
  • Alternative Therapies
  • Long-term Care Strategies

Research focuses on developing evidence-based approaches for medication reduction while maintaining optimal symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.